ArticleJournal of breast cancer2025
Clinical Implication of Subcategorizing T2 Category in Metaplastic Breast Cancer.
Article in Journal of breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeIn the tumor, node, metastasis staging system for metaplastic breast cancer (MBC), the T2 category, encompassing a border spectrum of tumor sizes than T1 category, curiously lacks subcategorization.
methodsUsing the Surveillance, Epidemiology, and End Results database, data of 767 women diagnosed as T2N0-2 MBC between 2004 and 2016 were analyzed. The optimal tumor size cutoff was determined using X-tile software to facilitate the subclassification of T2 tumors. A comparison of breast cancer-special survival (BCSS) was conducted across three subcategories, with a median follow-up duration of 44 months.
resultsOf 767 patients, 136 (17.7%) died. Based on Kaplan-Meier analysis, 30 mm and 40 mm were selected as the cutoff values. Ten-year BCSS rate was 90.2% in patients with breast tumors ≤ 30 mm (T2a), 80.2% in patients with breast tumors ≤ 40 mm (T2b), and 68.2% in patients with breast tumors ≤ 50 mm (T2c) (log-rank
conclusionFurther stratification within the T2 category could enhance the precision of prognostic predictions and facilitate the customization of adjuvant treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.